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Abstract: Breast-to-brain metastasis (BBM) often represents a terminal event, due to the inability of 
many systemic treatments to cross the blood-brain barrier (BBB), rendering the brain a sanctuary 
site for tumour cells. Identifying genetic variations that can predict the patients who will develop 
BBM would allow targeting of adjuvant treatments to reduce risk while disease bulk is minimal. 
Germ-line genetic variations may contribute to whether a BBM forms by influencing the primary 
tumour sub-type that presents, or by influencing the host-response to the tumour or treatment 
regimen, or by facilitating transition of tumour cells across the BBB and establish a viable brain 
metastasis. The role of mitochondrial DNA (mtDNA) variants specifically in BBM is underexplored. 
Consequently, using a sensitive deep-sequencing approach, we characterised the mtDNA variation 
landscapes of blood samples derived from 13 females who were diagnosed with early onset breast 
cancer and later went on to develop BBM. We also predicted the potential pathogenic significance 
of variations identified in all mtDNA-encoded oxidative phosphorylation (OXPHOS) proteins using 
3D protein structural mapping and analysis, to identify variations worthy of follow-up. From the 
70 variations found in protein coding regions, we reveal novel links between 3 specific mtDNA 
variations and altered OXPHOS structure and function in 23% of the BBM samples. Further studies 
are required to confirm the origin of mtDNA variations, whether they correlate with 1) the predicted 
alterations in mitochondrial function and 2) increased risk of developing breast brain metastasis 
using a much larger cohort of samples. 
Keywords: mtDNA; breast cancer; breast to brain metastasis; 3D protein structural mapping and 
analysis; OXPHOS and long PCR 
1. Introduction 
Breast neoplasms are currently the second highest cause of cancer related death in women. 
Although brain metastases are less common than lesions in the bone or lungs, they often represent a 
terminal event with a projected survival of just 3 to 6 months from diagnosis, with less than 20% of 
patients surviving more than 1 year [1–3]. Poor clinical outcome is due, in part, to the difficulty in 
treating the metastatic site, with systemic treatments generally being unable to penetrate the blood 
brain barrier. Predicting clinical outcome is also difficult due to the complicated interactions of 
metastatic cells with host homeostatic mechanisms, which metastatic cells ultimately exploit for their 
own survival and proliferation [4]. 
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The process of brain metastasis, including breast-to-brain metastasis (BBM), consists of a series 
of steps. In order that a clinically relevant brain lesion is observed, tumour cells must: 1) reach >1mm3 
by rapidly proliferating and establishing new vasculature, 2) invade the host cells and gain access to 
either the circulatory lymphatic or haematogenous systems, 3) survive the lymphatic or 
haematogenous systems and arrest in the capillary beds and extravasate into the brain, and 4) 
proliferate and form metastasis in the brain [4]. Despite this broad understanding of the metastatic 
process, the incidence of BBM is on the increase and there is consequently a need for better 
understanding of the BBM process as well as markers that could predict which patients will develop 
BBM, which in turn could improve current treatments for patients with BBM.  
Patient-derived blood samples are often used to identify associations between genetic variations 
in the germ-line and cancer prognosis [5,6]. Identifying such variations could help predict which 
patients may develop BBM, allowing the targeting of adjuvant treatments aimed at reducing risk 
while the disease bulk is minimal. 
MtDNA, which exists as multiple copies in the mitochondrial matrix, is 16,568 base pairs long 
and encodes 37 genes. These genes provide 13 key catalytic proteins of the oxidative phosphorylation 
(OXPHOS) system, as well as the 2 rRNAs (12S and 16S) and 22 tRNAs vital for their synthesis. Of 
the 13 mtDNA-encoded proteins, 7 contribute to complex I (NADH dehydrogenase), 1 contributes to 
complex III (cytochrome bc1 complex), 3 contribute to complex IV (cytochrome c oxidase) and 2 
contribute to complex V (ATP synthase).  
The OXPHOS system is composed of the mitochondrial respiratory chain (complexes I to IV) 
and ATP synthase (complex V). This system is vital for the production of cellular energy in the form 
of ATP and also has numerous secondary roles in other processes including calcium homeostasis [7], 
reactive oxygen species (ROS) production and signaling [8] and apoptosis [9,10]. Due to the 
importance of OXPHOS, variations in the mtDNA sequence, which can be germ-line or somatic, have 
the capacity to inflict profound effects on cellular function, contributing to or causing numerous 
human diseases (reviewed in [11]). As several hundred mtDNA molecules co-exist within a cell or 
tissue however, each with the capacity to hold different variations, a certain threshold must be met 
for a variation to exert an observable phenotypic effect [12]. The occurrence of multiple mtDNAs 
within a population is termed heteroplasmy. 
Alterations in OXPHOS, as a consequence of mtDNA variations, have a proposed role in 
metastasis [13]. For example, transmitochondrial hybrids (cybrids), formed through the cell-cell 
fusion of enucleate highly metastatic lung cancer cells and mtDNA deplete lung cancer cells with low 
metastatic potential, enhanced the recipient cell’s ability to form metastatic nodules in the lungs of 
mice following tail vein inoculation [14]. Consistent with this, the reciprocal mtDNA exchange 
suppressed the ability of the host cells to form metastatic nodules [14]. Despite the various studies 
that have looked into the incidence and predisposing roleof mtDNA variations in primary breast 
cancer [15–18] and the role of mtDNA variations in the metastatic process using in vitro cellular and 
mouse xenograft models [13-14, 46], no similar studies have been conducted in the context of BBM.  
As a first step towards determining whether mtDNA variations in the germ-line could influence 
the likelihood of developing breast to brain metastasis, in this study we determined the blood 
mtDNA variation landscapes of 13 breast to brain metastasis patients using an established, sensitive 
deep sequencing approach [19]. As expected, numerous mtDNA variations were detected relative to 
the revised Cambridge reference sequence (rCRS [23] [Genbank: NC_012920]). Consequently, in 
order to draw up a short-list of candidates worthy of follow up investiagtion, all of the non 
synonymous variations identified in mtDNA-encoded OXPHOS proteins were then inspected in 
detail in silico using the latest, best quality and homologous 3D protein structure data available to 
analyse and predict their potential functional impact on the OXPHOS system [20] and therefore 
potential links with the BBM process. Until now, this has only been possible for mtDNA-variations 
in complex III and IV genes [19, 20]. However, recent publication of the cryo-EM 3D structures for 
complexes I and V [28,29, respectively] means, for the first time, we can also gain insight into the 
impact of mtDNA-variations at the level of protein structure in these complexes. 
2. Materials and Methods  
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2.1 Breast to brain metastasis patients and DNA samples 
Thirteen whole blood DNA samples were obtained from a subset of the Prospective study of 
Outcomes in Sporadic vs Hereditary breast cancer (POSH) [21,22]. Specifically, these patients had 
developed breast-to-brain metastasis. Patients were aged 40 or younger, and had been diagnosed 
with invasive breast cancer between January 2000 and January 2008. They also had varying NPI 
(Nottingham prognostic index) scores, hormone receptor expression and treatment exposure (Table 
S1). The NPI is used to calculate the prognosis of breast cancer patients following surgery, taking into 
consideration the size of the lesion, the number of lymph nodes affected and the tumour grade (I-III). 
As a collective, the patients in this study had an average NPI score of just above 5.4, meaning 70% of 
patients had a projected survival of 5 years. 
2.2 Long PCR amplification and sequencing of complete mtDNAs 
Based on the method of Lloyd et al. 2015 [19], total DNA was extracted from the total blood of 
each patient using DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer’s instructions. 
100ng of total whole blood DNA of each patient, was amplified using two overlapping mtDNA 
specific primer pairs: CytbF and HumanLongR (Amplicon 1) or HumanLongF and CytbR (Amplicon 
2) to yield two halves of the mitochondrial genome in each case, which were then resolved by agarose 
gel electrophoresis, purified and quantified (Table S2). Amplicon 1 and 2 from each sample were 
pooled (0.65 nM each) and 1ng of DNA from each pool was used to construct 13 Truseq Nano libraries 
(Illumina) which were combined, sequenced with paired-end 2 X 150 reads on the Illumina MiSeq 
system (Department of Biochemistry, University of Cambridge).  
2.3 Identification of variations, determination of heteroplasmy and annotation 
Post sequencing, reads obtained from the Illumina Resequencing Workflow 
(http://supportres.illumina.com/documents/documentation/software_documentation/miseqreporter/miseq-
reporter-user-guide-15042295-b.pdf), were aligned against the rCRS [23] [Genbank: NC_012920] using 
the Burrows Wheeler Aligner (Galaxy Tools Version (GTv) 1.2.3). The rCRS, which represents 
haplogroup H2a2, is currently the standard sequence used for identifying the presence of mtDNA 
variations.  Refinement of the initial alignment was then conducted through the marking and 
removal of duplicate reads, using Picard beta (GTv 1.56.0), followed by setting up regions for indel 
realignment, realignment around indels, identification of co-variates and recalibration of quality 
scores using the GATK tools beta (GTv 0.0.4, 0.0.6, 0.0.5 and 0.0.6, respectively).  
Variant calling was carried out on the processed alignment with the GATK unified genotyper 
(GTv 0.0.6) to identify regions of the sequences that diverged from the rCRS. Complete processing of 
reads through this workflow removed the presence of several suspected false variations (G3483C, 
T3488A, A3492C and 3492insC), that frequently reside in the unprocessed variant files generated 
directly by the Illumina Resequencing Workflow.   
To further minimise miscalling of variations, those which had previously been identified as 
"false" variants due to misalignments around homopolymer tracts or sequencing errors by Ju et al. 
(A302C, C309T and C3106A; [27]) were discarded. Finally, variants at sites in the rCRS which are 
known to contain rare alleles (A263, A750, A1438, A8860 and A15326) were not considered in further 
analysis [23]. 
To confirm the presence and calculate the heteroplasmy of each of the remaining variations a 
minimum read quality (Phred) score of 30 (Q30) was applied, this means that there is a very low 
likelihood (just a 0.01% chance) that the variations detected were due to sequencing error. To be 
confident that the variants called were not due to sequencing error a stringent heteroplasmy cut off 
of ≥1% was applied, i.e. the number of mtDNA molecules harboring the variant had to be ≥1% or 
≤99% to be considered heteroplasmic. If <1% then the variant would be considered homoplasmic 
wild-type. If >99% then the variant would be considered homoplasmic (pure) mutant. To determine 
heteroplasmy, 250 of the Q30-reads (with the duplicates removed) in the alignment were chosen at 
random and then heteroplasmy was calculated by dividing the depth of reads with the variant 
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nucleotide by 250, and then expressed as a percentage. The presence of variations was further 
confirmed by visually inspecting the full alignments using Tablet[47]. Annotation of the identified 
variations was conducted manually by inputting variations into Mitowheel 
(http://mitowheel.org/mitowheel.html) to ascertain their locus and precise position in the 
mitochondrial genome. All new mtDNAs generated have been submitted to GenBank with the 
following accession numbers (MF317865- MF317877). 
 
2.4 Prevalence of variations in normal/healthy (control) bloods and pathologic tissues 
Previous disease associations of the variations were established through MITOMAP 
(http://www.mitomap.org/MITOMAP) and the human mitochondrial database (HmtDB; 
http://www.hmtdb.uniba.it/hmdb/). The HmtDB was also used to determine the prevalence of 
variations within bloods obtained from normal, healthy individuals (as controls). The HmtDB 
contains over 28,196 and 3,539 mitogenomic sequences obtained from the tissues of normal, healthy 
subjects and patients, respectively. Variation identification by HmtDB is based on the Reconstructed 
Sapiens Reference Sequence (RSRS) and Phylotree mtDNA tree Build 17), this means certain 
variations identified in the BBM mtDNAs relative to the rCRS, do not generate hits using the HmtDB 
(a full list can be found at Phylotree: http://www.phylotree.org/resources/RSRS_vs_rCRS.htm). 
 
2.5 Identifying functional candidates using three-dimensional protein structure mapping and analysis 
Three-dimensional (3D) protein structure mapping and analysis was used to examine and 
predict the functional impact of all non synonymous variations identified in mitochondrial encoded 
proteins. This approach was developed and validated on a number of complex III and complex IV 
variations associated with a broad range of human diseases, and has more recently been used to 
identify mtDNA variations worthy of follow up investigations using in vitro functional assays in 
glioblastoma [19,20, respectively]. Subsequently, several variations found in GBM MT-CYBs and 
predicted to be of significance have been shown to influence complex III properties such as activity 
or drug-sensitivity, when individually introduced into yeast, validating the usefulness of the 
approach [48]. The recent high profile publications of both the mammalian complex I [28] and 
complex V [29] cryo-EM structures, means here, for the first time the pathogenicity of mtDNA 
variations within these complexes can also be predicted, something which precluded the earlier 
studies [19, 20]. 
In brief, the 13 human mitochondrial protein sequences were used to find the latest, best quality 
and most similar OXPHOS complex structures for complexes I, III, IV and V available from RCSB 
PDB (complex I – [PDB:  5LC5] (B. taurus) [28]; complex III – [PDB:1NTZ] (B. taurus) [30] & 
[PDB:1BE3] (B. taurus) [31] ; complex IV [PDB:2EIJ] (B. taurus) [32] and complex V [PDB:5ARA] (B. 
taurus) [29]. Similarity between human sequences and the new complex I and V models are shown in 
Table S3, while the others have been documented previously [20]. 
Relative location and conservation of variations between the human and model sequence 
alignments was identified using ClustalW2 [33] and then annotated with ESPript [34]. Variations 
were mapped to their most homologous associated structures and displayed in PyMOL (Schrödinger, 
LLC). In the case of complex I, maps were generated using the X-ray generated T. thermophilus 
[PDB:4HEA] model, as this was not possible using the cryo-EM generated B. taurus [PDB: 5LC5] 
model, which is not available with docked X-ray crystallographic data. Detailed analysis of the effect 
of variations, based on their proximity to important structural features within the models, was then 
performed on the most similar structures using COOT [35]. Following this, variations were classified 
into 1 of 5 distinct pathogenic categories: (i) frameshift, (ii) active site, (iii) binding pocket, (iv) protein 
interaction region or (v) non pathogenic.  
3. Results and Discussion 
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3.1. Generation of new complete mitochondrial genomes 
Long PCR and sequencing of whole blood DNA from BBM patients yielded 13 high quality new 
complete mitochondrial genomes (BBM1-13]. Each genome was compiled from 1,626,861 ± 196,610 
reads with a mean length of 150 ± 0.3 nucleotides (Table 1). These reads were then mapped against 
the revised Cambridge Reference Sequence (rCRS [23]), forming alignments with an average total of 
1,573,446 ± 196,129 reads and a mean depth of coverage per nucleotide of 14,224 ± 1,781 over the entire 
mitochondrial genome (Table 1).  
3.2 Highly variable mtDNA profiles 
In total, 330 variations were identified across the 13 mitochondrial genomes; this consisted of 
160 nucleotide positions that were found to be altered in just one or multiple samples (detailed in 
Table S4). The vast majority of the total variations (274/330, 83%) were nucleotide substitutions with 
the remaining variations being indels, including 36 insertions and 20 deletions.  
The average number of variations in each sample was 25.38 ± 15.98, with most variations 
occurring in BBM4 and BBM8, which contained 58 and 53, respectively. BBM6, BBM7 and BBM11 
contained just 11 variations each (Figure 1A). The range of heteroplasmy for each variation detected 
in each sample was also diverse, with no significant differences in the average heteroplasmy (72.03% 
± 34.84%) observed between samples (Figure 1B). The total number of variations and average 
heteroplasmy observed in this small cohort of individual samples did not appear to correlate with 
markers known to be associated with the likelihood of developing BBM, i.e. triple negative or Her2+, 
or ER- (see Rostami et al. for review [36]), nor whether the patient had been exposed to radio- or 
chemotherapy prior to the blood DNA being taken for analysis (Table S1), despite some studies 
showing chemotherapies can result in mtDNA instability [37]. This prompted us to look in more 
detail at the specific variations present.  
3.3 D-loop, mt nd4, mt-nd5 and mt cyb are variation hotspots 
Variations were identified in all regions of the mtDNA genome apart from mt nd3 (Figure 2A). 
Variations were predominantly situated in the displacement loop (D loop), a non coding control 
region and known “hotspot” for mtDNA variation in many cancers [38,39], which contained 45% 
(149/330) of all variations. 
In the coding regions, the largest number of variations (12%; 41/330) occurred in mt rnr2, which 
encodes for the mitochondrial 16S rRNA. Three other mitochondrial coding genes also contained a 
high number of variations: mt nd4 and mt nd5 (both encoding complex I subunits) each contained 5% 
(18/330) and mt cyb (encoding for a complex III subunit), which contained 6% (19/330) of the total 
variations. These patterns did not appear to be correlated with locus length (Figure 2B).  
3.4 Heteroplasmy, prevalence and disease-association characteristics of recurrent variations 
Seventy out of 160 variations appeared in 3 or more samples (Table S4). Thirty-two (46%) of the 
recurrent variations were identified in the D-loop and included: A73G, T152C, C299A, A301C, 302insC, 
T310C, 310insC, A16183C, C16256T, T16311C, T16326C and T16519C. The remaining 38 (54%) of the 
recurrent variations were present in the RNA-coding regions. The most frequently recorded 
variations were (in descending order of frequency): A2706G in mt rnr2, C7028T in mt co1, G11719A in 
mt-nd4, A12308G in mt tl2, C14766T in mt cyb, A11467G in mt nd4, G12372A in mt nd5 and G709A in 
mt rnr1.  
Broadly speaking, the recurrent variations could be categorised into two groups (Table S4):  
(1) a large group of almost 100% heteroplasmy, probably reflecting a germ-line origin. Among 
these, three subgoups were identified. Those which were found at a similar frequency in the bloods 
of BBM patients and normal subjects (T152C, T16311C and T16362C) and therefore unlikely to be of 
significance, those which were enriched by 10% or more frequent in the bloods of BBM patients than 
normal subjects (A11467G, G12372A, G709A, A12308G, T10463C and C16256T) and therefore 
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potentially significant, and finally, those which were depleted by ~10% or more in the bloods of BBM 
patients than normal subjects (G11719A, C14766T, A73G, A2706G, C7028T and T16519C). 
(2) a small group with reasonably low average heteroplasmy (34.5 ± 26 %), which could be of 
either germ-line or tumour cell origin. With the exception on A16183C, all of the variations in this 
group were enriched by ~10% or more in the bloods of BBM patients when compared to normal 
subjects (C299A, A301C, 302insC, A3105T, 3105insAC, T310C and 310insC) and therefore of potential 
significance. Interestingly, among the somatic variations detected in primary breast cancer cells, those 
somatic variations detected in the “D310 repeat region of the D-loop”, of which T310C and 310insC 
(this study) would be examples, have been promoted as marker for breast tumourigenesis [40]. 
302insC, T310C, C16256T, T16362C, G709A, T10463C, A11467G, G12372A, A12308G and A16183C have 
been detected in multiple tumour types, including breast and brain tumours previously; T16519C 
and A73G have been detected in multiple tumour types including brain tumours previously; and 
T310C and T16311C have been detected in melanoma and prostate, respectively, although not breast 
or brain tumours. T152C has been detected in ovarian and breast tumours. On the other hand, 
A2706G, C7028T, G11719A, C14766T, C299A, A301C, A3105T and 3105insAC have not been reported 
in tissues of patients with pathology previously (Table S4).  
Although, there is evidence that suggests mtDNA variations can play a role in primary breast 
cancer, e.g. the germ-line variations: T16189C [15], G9055A, T16519C, T239C and C16207T [16,17] are 
associated with breast cancer development susceptibility and G10398A is associated with higher 
breast cancer risk in African women [18], these were not among the recurrent variations in our cohort. 
3.5 Global structural maps 
Overall 116 variations were identified in protein coding regions, of these 79 (68%) were 
synonymous and 37 (32%) were non synonymous (Figure 3A). All non-synonymous variations in the 
mtDNA-encoded OXPHOS genes were mapped onto their corresponding structural homologs, 
yielding the first insight into their distribution across the complexes. Figure 4, which is a 
compendium of the 23 non-synonymous variations identified in all of the BBM patients, reveals a 
non-uniform distribution. Most variations were found in (in descending order): complex I, IV, III and 
V. The high frequency of variations in complexes I, IV and III can be accounted for by variation 
hotspots (again in descending order) in MT-ND1 and ND5 of complex I, MT-CO3 of complex IV and 
MT-CYB of complex III, respectively. MT-ATP6 also contained a couple of variations, while MT-CO1, 
MT-CO2, MT-ND2 and MT-ND6 each contained just one variation; MT-ND3, ND4, ND4L, and MT-
ATP8 (not shown), however, remained variation free. Among the non-synonymous variations, 48% 
(11 of 23) were conserved between the human sequences and the bovine models (Figure S1). Despite 
complex I containing most of the non-synonymous variations, just 30% (3 of 10) were conserved, 
followed by 40% in complex III (2 of 5), 60% in complex IV (4 of 6) and 100% in complex V (2 of 
2)(Figure 4, Figure S1 and Table S3). 
3.6 Three functional candidates identified 
Owing to the 61-91% identity that exists between the human sequences and the homologs ([19] 
and Table S3), we were able to perform, for the first time, detailed 3D structural analysis on all 
complexes of the OXPHOS system containing mtDNA-encoded subunits. Using this approach, we 
were able to predict just 3 out of the 23 non-synonymous variations were likely to have a functional 
impact at the level of protein structural changes, and could be put into previously defined 
structural/functional classes [19,20].  One occurred in a complex III ligand/inhibitor binding pocket 
region (class 3) and two occurred in protein-protein interaction regions (class 4), one in complex IV 
and one in complex V. The remaining variations, including all 10 in complex I, are predicted to be 
non-functional (Table 2). 
The absence, or very low frequency, of all 3 of the functional candidates in the bloods of normal 
healthy individuals further hints that the variations could be important. According to the HmtDB: 
the complex IV variation (E153G) has previously been documented in diabetes, while 
T14819insTTCTATA and S99P have not been previously been documented were not reported (Table 
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S4 and S5). Intriguingly, S99P has been reported as a somatic variant in the TCGAs-BRCA project of 
primary breast invasive carcinoma patients.   
3.7 Mechanistic insights  
The structural consequences of the 3 variations predicted to be functional are illustrated in 
Figures 5 and 7. 
Figure 5A to D depicts the structural consequence of the 14819insTCTATA in frame insertion on 
the only mtDNA-encoded subunit of Complex III: MT-CYB. Complex III is at the centre of the 
OXPHOS system, and catalyses the transfer of electrons from ubiquinol to cytochrome c, which is 
coupled with the translocations of protons across the inner mitochondrial membrane. Complex III is 
also a major site for ROS production. MT-CYB lies at the centre of dimeric complex III, and forms 
intimate interactions with 20 to 22 additional subunits (10 to 11 per MT-CYB monomer) that are 
nuclear DNA-encoded. The subunit contains two hemes and two inhibitor binding sites, the Qo and 
Qi sites. Although the codons remain in register, the introduction of 6 new nucleotides at position 
14819 of the mitochondrial genome eventually causes a serine to phenylalanine substitution at 
position 25 before the addition of a further 2 new amino acids, a tyrosine and a threonine at position 
26 and 27, respectively, of the MT-CYB polypeptide (Figure S2). Although it is difficult to model the 
precise effects of these changes, such a substantial change is unlikely to be easily accommodated by 
the wild type protein (Figure 5A, C) and we predict local mis-folding of the mutant MT-CYB in a 
region proximal to the ubiquinol/ubiquinone binding site (the Qi-site; Figure 5B). The mis-folding 
could also affect the surface of MT-CYB (Figure 5C, D), disrupting its interactions with the nuclear 
subunits, and therefore the stability of complex III. Taken together, 14819insTCTATA is likely have 
an effect on complex III activity. As inhibitors can also bind to the Qi-site, this variation could also 
influence the efficacy of complex III inhibitors eliciting mitochondrially-mediated apoptosis.   
A9664G causes the amino acid substitution E153G in MT-CO3. Complex IV, which is the terminal 
enzyme of the MRC that catalyses the electron transfer from cytochrome c to oxygen, which (like in 
complex III) is also coupled to proton translocation across the inner mitochondrial membrane. MT-
CO3 forms a homodimer at the centre of complex IV. Although MT-CO3 does not house any active 
sites/binding pockets, through its interactions with MT-CO1 and various nuclear encoded subunits 
e.g. COX6A, it is thought to play a key role in the formation and therefore stabilisation of complex IV 
dimer [41]. In wild type MT-CO3, E153 occupies a position on the surface of MT-CO3 and interacts 
with alanine at position 13 of the nuclear-encoded subunit COX6A (Figure 6A). The E153G 
substitution is predicted to eliminate a hydrogen bond interaction (Figure 6B) that usually occurs 
between the large, negatively charged wild type glutamic acid residue of MT-CO3 and the smaller 
hydrophobic alanine of nuclear COX6A, potentially undermining the interaction between E153G and 
COX6A (Figure 6C, D). In summary, E153G could affect complex IV stability and therefore activity. 
Consistent with this view, knockdown of the COX6A subunit (although a more severe scenario than 
E153G) has been shown to reduce activity of complex IV [42–44]. 
T8821C causes an S to P substitution at position 99 of the MT-ATP6 polypeptide (Figure 7), which 
forms part of the F0 region of complex V. Complex V is the primary producer of ATP in eukaryotic 
cells, and in addition to the hydrophobic F0 region that traverses the inner mitochondrial membrane, 
it has a hydrophilic F1-ATPase region that protrudes like a ‘lollipop’ head into the mitochondrial 
matrix. In addition to MT-ATP6 (also known as the a-subunit) the F0 region is formed of an additional 
mtDNA-encoded subunit (MT-ATP8, also referred to as A6L-subunit), several nuclear encoded 
subunits (e, f, g, DAPIT, 2 hydrophobic alpha-helices of b), a proteolipid, and the c8-ring (‘rotor’).  
The F0 and F1 regions are linked via the subunits OSCP, d, F6 and the hydrophilic portions of subunit 
b, referred to as the peripheral stalk. It is proposed that complex V drives the protons that arise in the 
inter membrane space (IMS) as a result of MRC activity through two half-channels formed by MT- 
ATP6 and the ‘rotor’. In one half channel, conserved Glu58 in one of the c-subunits receives a proton 
from the IMS, which induces the c-ring to rotate, with the protonated Glu residues moving away 
from the static portions of the F0 region (the ‘stator’ which includes the two mtDNA-encoded 
subunits as well as components of the peripheral stalk). Once the protonated Glu residues have 
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moved almost a full circle around the ‘rotor’, returning to the static portion of the F0 region, the other 
half channel provides an exit for the protons into the matrix. The resulting in deprotonation of the 
Glu residue, makes it ready to receive another round of protonation via the IMS. The mechanical 
energy created by the rotation, is transmitted via subunits gamma, sigma and epsilon (the ‘shaft’), 
causing conformational changes in the alpha and beta subunits (the ‘blades’) of the F1 region, and  
ultimately ATP hydrolysis (reviewed in [29]). Complex V is often referred to as a Brownian ratchet 
as rotation of the c-ring occurs through Brownian motion, but it is also referred to as a turbine as the 
enzyme has all the parts required to make a simple turbine (a rotor, stator, shaft and blades). Wild 
type MT-ATP6 is a 6-alpha helical bundle, whose tertiary folds are likely to be stabilised by the 12 
proline residues (Figure S1). These proline-mediated kinks are likely to be indispensable for the 
positioning of MT-ATP6 close to the nuclear-encoded subunits of the c-ring rotor, as well as subunit 
b that forms part of the stator, and MT-ATP8, whose function of which is of yet unknown. The 
introduction of an additional proline residue, downstream of a conserved proline at position 94 of 
MT-ATP6 (Figure S1, Figure 7), is likely to affect thermodynamics of the whole subunit, and as a 
consequence, the numerous inter-helical interactions of MT-ATP6 mentioned above [45], this in turn 
could reduce complex V activity. 
3.8 Prevalence of functional candidates in patient bloods 
The detailed structural modelling suggests that altogether just 3 out of the 13 (23%) BBM patients 
carried a single pathogenic variation: BBM4 carries T14819insTTCTATA in complex III, BBM12 carries 
E153G in complex IV, and BBM2 carries S99P in complex V. While the possibility that D-loop, rRNA, 
tRNA and synonymous variations could also affect the OXPHOS function through a variety of 
mechanisms, the current lack of in silico tools available to accurately predict the structural/functional 
effect of such variations on OXPHOS proteins limits informative interpretation. 
3.9 Summary and future prospects 
Although more patients are surviving primary breast cancer, more and more are developing 
secondary metastases, including to the brain. Although there are existing markers that relate to the 
likelihood of developing BBM (e.g. triple negative or Her2+, or ER-), more needs to be done to fully 
understand the process of BBM and develop additional markers that predict whether a patient will 
develop BBM. MtDNA variations are known to play a role in various diseases, including some 
cancers. With ever improving and more cost-effective sequencing technologies, an increasing number 
of mtDNA variations are being detected that are associated with disease. However, proving their role 
in processes like BBM remains difficult, one reason being that it is impossible to introduce single 
mtDNA variations into human mtDNA and observe direct phenotypic effects.  
Our focus here was two-fold: to screen the bloods of BBM patients using an established and 
sensitive deep sequencing approach for mtDNA variation detection (and to predict their effect on 
mitochondrial function using an equally established 3D structural modelling approach [19]). We 
reveal that the vast majority of mtDNA protein-coding variations detected in the majority of patients 
tested are not predicted to have a major impact on mitochondrial function. This said, 3 of the mtDNA 
variations detected in three of the patients were predicted to have an impact at the level of OXPHOS 
protein structure. The potential multiple origins of the mtDNA variations (e.g. neutrophil, monocyte, 
myeloid dendritic, natural killer, T and B [49], as well tumour circulating cells [4]) detected in the 
bloods, as well as the different selective pressures which may act upon them, however, make it 
difficult to fully predict their significance on the process of BBM (even if they are predicted to evoke 
a change on the OXPHOS system), and requires further investigation using matched primary 
tumour-blood-secondary tumour samples to confirm their origin. Other future work could include 
determining how the 3 mtDNA variations correlate with 1) the predicted alterations in mitochondrial 
function using in vitro studies and 2) with increased risk of developing breast brain metastasis using 
a much larger cohort of patient samples. This study also serves as a resource by highlighting a list of 
several mtDNA variations which are predicted to be non-functional and therefore not worthy of 
further investigation, which should help scientists and clinicians avoid wasting resources. Such a 
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systematic approach of analyzing mtDNA variations could help improve our understanding of their 
role in the process of BBM as well as aid the development of markers that predict whether patients 
develop BBM in the future. 
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Tables with captions 
Table 1. Summary of sequencing read statistics used to generate new complete breast-to-brain 
metastasis blood mtDNAs. 
Abbreviation: nt - nucleotide, DOC - depth of coverage 
Table 2. Heteroplasmy, prevalence of non-synonymous variations in the mtDNA complex genes 
identified within the mtDNA landscapes of breast-to-brain blood samples. 
Locus 
Specific 
Nucleotide 
Variant 
Amino Acid 
change 
Average 
heteroplasmy (% ± 
SD) 
% 
Hmt
DB 
% 
BBM 
Specific Sample 
IDs (BBM) 
MT-ND1 A3796G T164A 99.6* 0.5 7.7 6 
MT-ND1 C3992T T229M 99.2* 0.7 7.7 10 
MT-ND1 A4024G T240A 99.2* 0.6 7.7 10 
MT-ND1 T4216C Y304H 99.4±0.3* 9.9 15.4 1 and 12 
MT-ND2 A4917G N150D 98.6±0.9* 4.7 15.4 1 and 12 
MT-ND5 A12397G T21A 99.6* 0.5 7.7 5 
MT-ND5 C12557T T74I 98.4* 0.3 7.7 4 
MT-ND5 G13813A V493I 99.6* <0.1 7.7 5 
MT-ND5 G13889A C518Y 99.6* 0.1 7.7 10 
MT-ND6 A14582G V31A 99.6* 0.6 7.7 10 
MT-CYB C14766T T7I 98.9±0.8* 77.3 46.2 1/ 4/ 8/ 9/ 12/ 13 
MT-CYB A14793G H16R 99.6±0.0* 2.2 15.4 9 and 13 
MT-CYB 
T14819insTTCT
ATA 
S25 2.4 - 7.7 12 
MT-CYB A15218G T158A 100±0.0* 1.9 7.7 9 
MT-CYB C15452A L236I 99.4±0.9* 9.1 15.4 1 and 12 
MT-CO1 G6267A A122T 98.8* 0.2 7.7 2 
MT-CO2 T8265C L227P 24.8 <0.1 7.7 4 
MT-CO3 C9469T T88I 100* 0.1 7.7 13 
MT-CO3 G9477A V91I 99.8±0.3* 4.0 15.4 9 and 13 
MT-CO3 A9664G E153G 98.8* 0.1 7.7 4 
Sample ID Total 
number of 
reads 
Number 
of reads 
mapped 
Mean 
read 
length 
Reads 
Mapped 
(%) 
Mean 
DOC/nt 
Accession 
No 
BBM1 1286809 1244758 150 97 11255 MF317865 
BBM2 1652912 1598870 150 97 14471 MF317866 
BBM3 1398435 1354576 150 97 12236 MF317867 
BBM4 1733369 1675403 150 97 15133 MF317868 
BBM5 1606805 1505339 150 94 13587 MF317869 
BBM6 2080624 2044788 150 98 18515 MF317870 
BBM7 1616133 1587251 150 98 14358 MF317871 
BBM8 1540641 1482632 150 96 13398 MF317872 
BBM9 1709391 1649532 150 96 14911 MF317873 
BBM10 1796414 1746692 150 97 15804 MF317874 
BBM11 1517582 1475338 150 97 13331 MF317875 
BBM12 1709260 1623266 150 95 14655 MF317876 
BBM13 1500821 1466356 150 98 13252 MF317877 
       
Average 1626861 1573446 150 97 14224 
 
 
       
Standard 
Deviation 
196610 
 
196129 
 
0.3 
 
1.2 1781 
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MT-CO3 A9667G N154S 99.2* 0.7 7.7 9 
MT-
ATP6 
T8821C S99P 83.2 <0.1 7.7 2 
MT-
ATP6 
G8989A A155T 97.2 <0.1 7.7 12 
 
Grey shading indicates variation classed as functional at the level of protein structural changes. The 
unshaded variations are classified as non-functional. %hmtDB and %BBM indicate prevalence in the 
human mitochondrial database and BBM cohort (this study), respectively. *Signifies homoplasmic 
(pure) mutant (see materials and methods).  
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Figures with captions 
 
Figure 1. Total number (A) and average heteroplasmy (B) of mtDNA variations in breast-to-brain 
metastasis patient blood mtDNAs. Error bars indicate standard deviation. 
  
Figure 2. Presence of variations in breast-to-brain metastasis patient blood across mtDNA loci. (A) 
Total number of mtDNA variations identified in both coding and non-coding loci. (B) Total number 
of variations expressed per nucleotide in each of the mtDNA loci.  
  
Figure 3. Pattern of synonymous and non-synonymous mtDNA variations in breast-to-brain blood 
mtDNAs. (A) Total and (B) across loci.   
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Figure 4. Global map of non-synonymous variations identified in the mitochondrial OXPHOS proteins of breast-to-brain metastasis patient blood mtDNAs. Variations 
mapped to T. thermophilus complex I homologues [PDB:4HEA], B. taurus complex III homologue [PDB:1BE3], B. taurus complex IV homologue [PDB:2EIJ] and B. taurus 
complex V homologoue [PDB: 5ARA]. The carbon alphas of residues that are conserved and non-conserved between the human sequences and the bovine models are 
highlighted as red and blue spheres respectively, including for complex I eventhough the T. thermophilus structure is shown. The conserved residue N150D is not shown 
as there is no equivalent residue present in 4HEA 
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Figure 5.  Structural consequences of the class 3 binding pocket variation 14819insTCTATA. The 
variation causes a serine to phenylalanine substitution and the addition of two amino acids at 
positions 25-27 of the complex III protein MT-CYB. MT-CYB is rendered as a space filling model 
(orange), with (A) the wild type Qi-site shown with the deeply buried heme (green) and bound 
ubiquinone (magenta; PDB 1NTZ). (B) The amino acid changes induced by the variation occur in the 
vicinity of the Qi-site (in red). (C) The surface of the wild type MT-CYB monomer. (D) The variant is 
likely to cause local mis-folding of MT-CYB (in red), disrupting its interaction with surrounding 
nuclear encoded subunits. Such changes to the MT-CYB Qi-site and surface are likely to interfere with 
ubiquinone/ubiquinol binding, and ultimately complex III activity.  
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Figure 6.  Structural consequences of the class 4 interaction variation A9664G. (A) Wild type E153 
(blue sticks) in MT-CO3 (yellow ribbons) forms an interaction with A13 (cyan sticks) in COX6A (grey 
ribbon).  (B) The variant G153 (red sticks) results in the loss of a hydrogen bond with A13. (C) The 
wild type MT-CO3 is shown as a surface model, showing E153 (blue) forms a tight interaction with 
A13 of COX6A (cyan). (D) Surface illustration of variant G153 (red), which no longer interacts with 
COX6A, which could affect the stability of complex IV. 
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Figure 7.  Structural consequences of the class 4 variation T8821C. Wild type MT-ATP6 (light green) 
is shown as a surface model and is formed of six kinked alpha-helices that stabilise the subunit and 
allow it to form intricate inter-helical interactions with subunit b (wheat), MT-ATP8 (not shown) and 
the c-ring (grey). Together with the hydrophobic portions of subunit b and MT-ATP8, MT-ATP6 form 
the static part of the F0 region, with the c-ring forming the rotary portion. It is likely that several 
proline residues (blue), conserved between the human sequence and the bovine model, are 
responsible for the kinks observed in MT-ATP6. The substitution of a serine for a proline (red) at 
position 99 in one of the helices, is likely to interfere with tertiary fold and destabilise the protein and 
disrupt its interactions, influencing complex V activity.  
 
 
 
 
 
 
 
 
